Related references
Note: Only part of the references are listed.Cilostazol mitigates mesenteric ischemia/reperfusion-induced lung lesion: Contribution of PPAR-γ, NF-κB, and STAT3 crosstalk
Abdallah M. Gendy et al.
LIFE SCIENCES (2021)
Neuromuscular junctions are stable in patients with cancer cachexia
Ines Boehm et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
mTORC1 signalling is not essential for the maintenance of muscle mass and function in adult sedentary mice
Nicole Ebner et al.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2020)
Macrophages potentiate STAT3 signaling in skeletal muscles and regulate pancreatic cancer cachexia
Surendra K. Shukla et al.
CANCER LETTERS (2020)
JNK signaling contributes to skeletal muscle wasting and protein turnover in pancreatic cancer cachexia
Scott E. Mulder et al.
CANCER LETTERS (2020)
Imperatorin alleviates cancer cachexia and prevents muscle wasting via directly inhibiting STAT3
Linlin Chen et al.
PHARMACOLOGICAL RESEARCH (2020)
Understanding cachexia in the context of metastatic progression
Anup K. Biswas et al.
NATURE REVIEWS CANCER (2020)
Investigational drugs for the treatment of cancer cachexia: a focus on phase I and phase II clinical trials
Alessio Molfino et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2019)
Tumour-derived transforming growth factor-β signalling contributes to fibrosis in patients with cancer cachexia
Joanna D. C. C. Lima et al.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2019)
Lung cancer-derived extracellular vesicles induced myotube atrophy and adipocyte lipolysis via the extracellular IL-6-mediated STAT3 pathway
Wenjun Hu et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2019)
A systematic review of herbal medicines for the treatment of cancer cachexia in animal models
Bongki Park et al.
JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B (2019)
Cancer cachexia is defined by an ongoing loss of skeletal muscle mass
Vickie E. Baracos et al.
ANNALS OF PALLIATIVE MEDICINE (2019)
Cancer-associated cachexia
Vickie E. Baracos et al.
NATURE REVIEWS DISEASE PRIMERS (2018)
Alpinetin inhibits proliferation and migration of ovarian cancer cells via suppression of STAT3 signaling
Xuezhi Zhao et al.
MOLECULAR MEDICINE REPORTS (2018)
Alpinetin exerts anti-colitis efficacy by activating AhR, regulating miR-302/DNMT-1/CREB signals, and therefore promoting Treg differentiation
Qi Lv et al.
CELL DEATH & DISEASE (2018)
Selumetinib Attenuates Skeletal Muscle Wasting in Murine Cachexia Model through ERK Inhibition and AKT Activation
Yang Quan-Jun et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Blockade of the IL-6 trans-signalling/STAT3 axis suppresses cachexia in Kras-induced lung adenocarcinoma
A. Miller et al.
ONCOGENE (2017)
TNF-α and cancer cachexia: Molecular insights and clinical implications
Hetal J. Patel et al.
LIFE SCIENCES (2017)
L-carnitine ameliorates the liver inflammatory response by regulating carnitine palmitoyltransferase I-dependent PPARγ signaling
Fang Jiang et al.
MOLECULAR MEDICINE REPORTS (2016)
STAT3 in the systemic inflammation of cancer cachexia
Teresa A. Zimmers et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2016)
Understanding cachexia as a cancer metabolism syndrome
P. E. Porporato
ONCOGENESIS (2016)
Alpinetin attenuates inflammatory responses by suppressing TLR4 and NLRP3 signaling pathways in DSS- induced acute colitis
Xuexiu He et al.
SCIENTIFIC REPORTS (2016)
TNF alpha inhibits myogenic differentiation of C2C12 cells through NF-κB activation and impairment of IGF-1 signaling pathway
Q. Zhao et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2015)
Targeting of Fn14 Prevents Cancer-Induced Cachexia and Prolongs Survival
Amelia J. Johnston et al.
CELL (2015)
Preclinical Investigation of the Novel Histone Deacetylase Inhibitor AR-42 in the Treatment of Cancer-Induced Cachexia
Yu-Chou Tseng et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Skeletal muscle atrophy: Potential therapeutic agents and their mechanisms of action
Vikas Dutt et al.
PHARMACOLOGICAL RESEARCH (2015)
Alpinetin inhibits lung cancer progression and elevates sensitization drug-resistant lung cancer cells to cis-diammined dichloridoplatium
Lin Wu et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2015)
Preclinical Investigation of the Novel Histone Deacetylase Inhibitor AR-42 in the Treatment of Cancer-Induced Cachexia
Yu-Chou Tseng et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
L-Carnitine Ameliorates Cancer Cachexia in Mice Partly via the Carnitine Palmitoyltransferase-Associated PPAR-γ Signaling Pathway
Fang Jiang et al.
ONCOLOGY RESEARCH AND TREATMENT (2015)
Pioglitazone Treatment Increases Survival and Prevents Body Weight Loss in Tumor-Bearing Animals: Possible Anti-Cachectic Effect
Mercia Beluzi et al.
PLOS ONE (2015)
Small Molecule Agonists of PPAR-γ Exert Therapeutic Effects in Esophageal Cancer
Hiroshi Sawayama et al.
CANCER RESEARCH (2014)
Cancer cachexia: understanding the molecular basis
Josep M. Argiles et al.
NATURE REVIEWS CANCER (2014)
Nuclear transcription factor κB activation and protein turnover adaptations in skeletal muscle of patients with progressive stages of lung cancer cachexia
Celine M. Op den Kamp et al.
AMERICAN JOURNAL OF CLINICAL NUTRITION (2013)
Stat3 Activation Links a C/EBPδ to Myostatin Pathway to Stimulate Loss of Muscle Mass
Liping Zhang et al.
CELL METABOLISM (2013)
Alpinetin inhibits LPS-induced inflammatory mediator response by activating PPAR-γ in THP-1-derived macrophages
Ke Hu et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2013)
Alpinetin promotes Bax translocation, induces apoptosis through the mitochondrial pathway and arrests human gastric cancer cells at the G2/M phase
Zhenran Wang et al.
MOLECULAR MEDICINE REPORTS (2013)
Understanding the mechanisms and treatment options in cancer cachexia
Kenneth Fearon et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia
Andrea Bonetto et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2012)
Antiproliferative effect of alpinetin in BxPC-3 pancreatic cancer cells
Jian Du et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2012)
Heterogeneous time-dependent response of adipose tissue during the development of cancer cachexia
M. L. Batista et al.
JOURNAL OF ENDOCRINOLOGY (2012)
Definition and classification of cancer cachexia: an international consensus
Kenneth Fearon et al.
LANCET ONCOLOGY (2011)
PPARγ ligands, rosiglitazone and pioglitazone, inhibit bFGF- and VEGF-mediated angiogenesis
Ahmad Aljada et al.
ANGIOGENESIS (2008)
SOCS 3 and PPAR-gamma ligands inhibit the expression of IL-6 and TGF-beta 1 by regulating JAK2/STAT3 signaling in pancreas
Ji Hoon Yu et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2008)
Adipose atrophy in cancer cachexia: morphologic and molecular analysis of adipose tissue in tumour-bearing mice
C. Bing et al.
BRITISH JOURNAL OF CANCER (2006)
Prevention of cancer cachexia by a novel nuclear factor κB inhibitor in prostate cancer
K Kuroda et al.
CLINICAL CANCER RESEARCH (2005)
GW9662, a potent antagonist of PPARγ, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARγ agonist rosiglitazone, independently of PPARγ activation
JM Seargent et al.
BRITISH JOURNAL OF PHARMACOLOGY (2004)
Share Paper
